ST1326, a selective CPT1A inhibitor, has an oral formulation (Teglicar) and has been tested in Phase 2 studies for the treatment of type 2 diabetes, where it demonstrated an excellent safety profile.[20, 21] We then treated SCC1 and Tu686 cells with CPI‐613 and ST1326, alone or in combination. This evidence concerns the gene CPT1A and type 2 diabetes mellitus.